Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 7.5/650 vs ADEFOVIR DIPIVOXIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.,Treatment of chronic hepatitis B in pediatric patients aged 12 years and older.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
10 mg orally once daily on an empty stomach.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Terminal elimination half-life is 7.5 hours (range 5–10 h); clinically, supports once-daily dosing with dose adjustment for renal impairment.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Adefovir dipivoxil is rapidly converted to adefovir by esterases. Adefovir is not significantly metabolized; it is eliminated renally by a combination of glomerular filtration and active tubular secretion. No CYP450-mediated metabolism.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Renal (90% as unchanged drug via active tubular secretion); biliary/fecal (<5%)
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
≤4% (low binding; negligible affinity for serum proteins)
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
0.4 L/kg (392 L in adults); indicates extensive tissue distribution (including liver).
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Oral: 59% (range 40–70%); prodrug adefovir dipivoxil is rapidly converted to adefovir.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Cr Cl ≥50 m L/min: 10 mg every 24 hours; Cr Cl 30-49 m L/min: 10 mg every 48 hours; Cr Cl 10-29 m L/min: 10 mg every 72 hours; Hemodialysis: 10 mg every 7 days after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
No adjustment required for mild-moderate hepatic impairment (Child-Pugh A or B). Not studied in severe (Child-Pugh C).
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Approved for age ≥12 years: 10 mg orally once daily. For age <12 years, use is not established.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Monitor renal function; adjust dose based on Cr Cl. No specific dose adjustment solely for age.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
WARNING: SEVERE ACUTE EXACERBATION OF HEPATITIS B, NEPHROTOXICITY, HIV RESISTANCE, and LACTIC ACIDOSIS/HEPATOMEGALY WITH STEATOSIS. See full prescribing information for complete boxed warning.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Severe acute exacerbation of hepatitis B upon discontinuation of therapy,Nephrotoxicity: monitor renal function, especially in patients at risk or with pre-existing renal impairment,HIV resistance: test for HIV before initiation in patients with unknown HIV status,Lactic acidosis and severe hepatomegaly with steatosis,Use with caution in elderly, renal impairment, or concomitant nephrotoxic agents
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Hypersensitivity to adefovir dipivoxil or any component of the formulation
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
No clinically significant food interactions; can be taken with or without food. Avoid high-fat meals if gastrointestinal intolerance occurs.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. In first trimester, risk cannot be excluded; use only if benefit outweighs risk. In second and third trimesters, potential for fetal harm exists; consider alternative therapy.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
It is unknown whether adefovir is excreted in human breast milk. Animal studies indicate it is present in rat milk. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy or for 2 weeks after last dose.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Pregnancy may increase renal clearance; however, specific pharmacokinetic data are lacking. Dose adjustment is not routinely recommended but may be necessary if renal function changes. Use standard dose of 10 mg once daily with monitoring of renal function and HBV DNA levels.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Monitor renal function closely; dose adjust for Cr Cl <50 m L/min. Check LFTs and HBV DNA every 3 months. Avoid in decompensated cirrhosis. HIV co-infected patients require concomitant antiretroviral therapy due to risk of HIV resistance. Prolonged therapy may lead to adefovir-resistant HBV mutations (rt A181V/T, rt N236T).
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
Take with or without food at the same time daily.,Do not stop taking without consulting your doctor; stopping may cause severe hepatitis flare.,Report any signs of kidney problems (decreased urination, swelling) or lactic acidosis (unusual muscle pain, trouble breathing).,Regular blood tests are required to monitor liver and kidney function.,Use effective contraception during treatment if you or your partner can become pregnant.,Avoid alcohol and other medications that can damage the liver or kidneys without medical advice.
No interactions on record
"Coadministration of adefovir dipivoxil and tenofovir disoproxil may reduce the antiviral efficacy of tenofovir by competing for renal tubular secretion via organic anion transporters (OATs) and potentially intracellular phosphorylation pathways. This competition can decrease tenofovir's intracellular active metabolite concentrations, leading to suboptimal viral suppression and increased risk of treatment failure in patients with chronic hepatitis B."
"The serum concentration of Teriflunomide can be increased when it is combined with Adefovir dipivoxil."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 7.5/650 vs ADEFOVIR DIPIVOXIL, answered by our medical review team.
ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. ADEFOVIR DIPIVOXIL is a Antiviral that works by Adefovir dipivoxil is a prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. It is phosphorylated intracellularly to adefovir diphosphate, which inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate deoxyadenosine triphosphate and causing DNA chain termination after incorporation into viral DNA.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 7.5/650 and ADEFOVIR DIPIVOXIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. The standard adult dose of ADEFOVIR DIPIVOXIL is: 10 mg orally once daily on an empty stomach.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 7.5/650 and ADEFOVIR DIPIVOXIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . ADEFOVIR DIPIVOXIL is classified as Category C. Adefovir dipivoxil is an FDA Pregnancy Category C drug. Animal studies have shown teratogenicity (malformations, embryo-fetal toxicity) at doses 23 times the human therapeutic dose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.